Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2023

Note 8 - Accounts Payable and Accrued Expenses

At June 30, 2023 and December 31, 2022, accounts payable and accrued expenses consisted of the following ($ in thousands):


	June 30,		December 31,
	2023		2022
Accounts payable	$	8,058	$	11,535
Accrued compensation		700		1,195
Research and development		16,149		7,289
Other		287		278
Total accounts payable and accrued expenses	$	25,194	$	20,297